← Leaderboards
Zhangjie Wang
Glycan Therapeutics Corporation
$4,365,125
Attributed
$4,365,125
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$4,365,125 · 2
By mechanism
R44$4,365,125 · 2
Top collaborators
No co-investigators on record.
Most similar at Glycan Therapeutics Corporation
Same institution · by research overlap
- Vijayakanth Pagadala$12,153,122
- Yongmei Xu$1,933,798
- Guowei Su$5,499,306
- Katelyn Arnold$1,234,308
Others in their field
Other Rising Stars on “Heparitin Sulfate”
- Edwin Manuel · Beckman Research Institute/City Of Hope$1,582,219
- Shivakumar Devaiah Pattada · Biostrategies, Lc$1,499,034
- Jin Wei · Boston Medical Center$1,386,531
- Xin Hu · Emory University$1,173,750
- Christopher B Toomey · University Of California, San Diego$1,148,203
- Ryan Joseph Weiss · University Of Georgia$907,503
Research focus
Heparitin SulfateDesignIn VivoSuccessSmall Business Innovation Research GrantOligosaccharidesPolysaccharidesUniversitiesHeparinReportingInflammatory ResponseSulfateBiological ProcessPhase 2 StudyMouse ModelInjuryLabelNorth CarolinaPhase 1 StudySubcutaneousAcetaminophenInflammatoryHourAmerican
Grant awards (5)
Development of heparan sulfate-based therapeutics to treat inflammatory diseases$50,000
R44 · FY2025 · GM · contact PI
Development of heparan sulfate-based therapeutics to treat inflammatory diseases$1,463,275
R44 · FY2024 · GM · contact PI
Development of analytical methods for glycosaminoglycans from biological sources$988,771
R44 · FY2023 · GM · contact PI
Development of heparan sulfate-based therapeutics to treat inflammatory diseases$874,308
R44 · FY2023 · GM · contact PI
Development of analytical methods for glycosaminoglycans from biological sources$988,771
R44 · FY2022 · GM · contact PI